Table 2.
Review of published antimicrobial susceptibility results for Myroides spp.
| Myroides spp. | # Of isolates | #S | % S | Citation |
|---|---|---|---|---|
| Amikacin | 161 | 1 | <1 | 4–7, 9, 10, 17, 21–34, 36, 40, 41, this report |
| Amoxicillin or ampicillin | 83 | 28 | 33.7 | 13, 17, 28, 32, 35, 36, 41 |
| Amoxicillin/clavulanate | 13 | 4 | 30.8 | 4, 10, 13, 28, 32, 36 |
| Aztreonam | 156 | 1 | <1 | 4–6, 10, 13, 17, 21, 22, 25, 26, 28, 30–33, 35, 36, 40, 41, this report |
| Cefepime | 129 | 1 | <1 | 4–7, 10, 13, 17, 21–23, 25, 26, 28, 30–36, 41, this report |
| Cefoperazone | 43 | 0 | 0.0 | 40, 41 |
| Cefoperazone/sulbactam | 14 | 1 | 7.1 | 5, 36, 41 |
| Cefotaxime | 13 | 0 | 0.0 | 10, 13, 28, 30, 32, 33 |
| Cefoxitin | 10 | 0 | 0.0 | 13, 28, 32 |
| Ceftazidime | 159 | 0 | 0.0 | 4–7, 9, 10, 13, 17, 21, 22, 25, 28, 30–36, 38, 40, 41, this report |
| Ceftazidime/avibactam | 2 | 0 | 0.0 | 24, this report |
| Ceftolozane/tazobactam | 1 | 0 | 0.0 | this report |
| Ceftriaxone | 62 | 0 | 0.0 | 5, 7, 10, 22, 23, 26, 33, 40, 41, this report |
| Cefuroxime | 4 | 0 | 0.0 | 10, 13, 32 |
| Chloramphenicol | 21 | 1 | 4.8 | 10, 20, 28, 41 |
| Ciprofloxacin | 163 | 13 | 8.0 | 4–7, 9, 10, 17, 20–23, 25–31, 33–36, 38–41, this report |
| Colistin | 91 | 0 | 0.0 | 17, 21, 25, 28, 31, 32, 36, 41 |
| Ertapenem | 4 | 0 | 0.0 | 38, this report |
| Fosfomycin | 60 | 0 | 0.0 | 17, 24 |
| Gentamicin | 161 | 0 | 0.0 | 4–7, 9, 10, 17, 21–34, 36, 40, 41, this report |
| Imipenem | 158 | 3 | 1.9 | 5, 6, 9, 10, 13, 17, 21–26, 28, 30, 31, 33–36, 38–41 |
| Levofloxacin | 102 | 20 | 19.6 | 4, 5, 9, 10, 17, 20, 22, 23, 25, 27, 30, 32, 33, 35, 36, this report |
| Meropenem | 122 | 32 | 26.2 | 4–8, 11, 13, 17, 22, 24–26, 29–34, 36–38, 41, this report |
| Meropenem/vaborbactam | 1 | 0 | 0.0 | this report |
| Minocycline | 19 | 19 | 100.0 | 31, 41, this report |
| Moxifloxacin | 61 | 56 | 91.8 | 10, 17, this report |
| Piperacillin/tazobactam | 124 | 17 | 13.7 | 4–7, 9, 10, 13, 17, 21–26, 29–33, 35, 36, 41, this report |
| Tetracycline | 41 | 0 | 0.0 | 10, 26, 28, 33, 40 |
| Tigecycline | 69 | 54 | 78.3 | 17, 28, 32, this report |
| Tobramycin | 58 | 1 | 1.7 | 4–6, 9, 21, 23, 24, 26–33, 40, this report |
| Trimethoprim/sulfamethoxazole | 155 | 50 | 32.3 | 4–7, 9, 10, 17, 21–24, 28–33, 35, 36, 38, 40, 41, this report |
When MICs were available, CLSI breakpoints for Enterobacterales were used for susceptibility interpretation. The cases in this report were considered 3 distinct isolates.